npg
a r t i c l e s
As a first line of defense, supramolecular assemblies known as inflammasomes activate inflammatory caspases including caspase-1, caspase-11 (mouse), and caspase-4 and caspase-5 (human) in response to pathogenic invasion and cellular perturbation 1, 2 . Absent in melanoma 2 (AIM2)-like receptors and proteins containing nucleotide-binding domains and leucine-rich-repeats (NLRs) are inflammasome sensors that respond to a variety of pathogen-associated molecular patterns (including cytosolic double-stranded DNA and bacterial flagellin) as well as danger-associated molecular patterns (such as extracellular ATP, uric acid crystals, and reactive oxygen species) 3 . AIM2-like receptors and most NLRs contain a Pyrin domain (PYD), which recruits apoptosis-associated speck-like protein containing a CARD (ASC) through PYD-PYD interactions. ASC also possesses a CARD and links the PYD-containing sensor proteins to caspase recruitment, dimerization, and autoproteolytic activation through CARD-CARD interactions. Both PYD and CARD belong to the death domain (DD)-fold superfamily, which is characterized by a conserved six-helix bundle fold 4 , and interact through nucleated polymerization and filament formation 5, 6 . The NLR family proteins NLRBs (also known as NAIPs) do not contain a PYD or CARD and signal through the CARD-containing NLRC4 adaptor 7, 8 , which similarly recruits caspase-1 through CARD-CARD interactions 7, 9, 10 . Activated caspases proteolytically process pro-IL-1β and pro-IL-18. The mature cytokines, once released, initiate downstream signaling events leading to the transcription of many proinflammatory and antiviral genes 11 . Inflammatory caspase activation can also lead to pyroptotic cell death characterized by spillage of cellular contents.
CARD-CARD interactions are essential for the assembly of all inflammasomes. Therefore, it is not surprising that a number of CARD-only proteins (COPs) inhibit inflammasome formation and cytokine maturation [12] [13] [14] [15] [16] [17] [18] . Regulation by COPs has been proposed to arise because of selective pressure and a need for higher tolerance for inflammatory stimuli. Interestingly, rodents and primates all have caspase-1, but COPs are found only in higher primates, thus suggesting that these genes must have emerged after the human-mouse divergence 18 . The genes of proposed CARD-only inhibitors, COP1 (also known as Pseudo-ICE and CARD16), INCA (also known as CARD17), and ICEBERG (also known as CARD18), reside near the caspase-1 locus, as a result of a series of gene duplication events 19 . New stop codons have led to transcripts missing several downstream exons, thus resulting in the translation of CARDs lacking the caspase domain 20, 21 . INCA and ICEBERG share 83% and 53% identity, respectively, with caspase-1 CARD, and they may have evolved new mechanisms in their functions. Additionally, INCA and caspase-1 are simultaneously upregulated by IFN-γ in the human monocytic cell lines THP-1 and U937, and ICEBERG, but not INCA, is induced by lipopolysaccharide (LPS) and the cytokine TNFα 15, 16 . Therefore, INCA and ICEBERG may play distinct roles in different biological settings. flexible C-terminal SUMO tag (Fig. 1d) . Using both gold-standard and model-versus-map Fourier-shell-correlation plots, we generated a reconstruction of ~4.8-Å resolution, with resolved density for some large side chains ( Supplementary Fig. 1b-e) , including many at the interface (described below). The final caspase-1 CARD model was highly similar to the ICEBERG structure ( Supplementary Fig. 1f,g ).
Structure of the caspase-1 CARD filament
The caspase-1 CARD filament had an approximate diameter of 8 nm and an inner hole of <1 nm (Fig. 2a) . On the basis of an extended conformation of the ~39-residue linker between the CARD and the caspase domains in caspase-1, the closely packed caspase-1 CARD in the filament would bring the local concentration of the caspase domain to ~3.1 mM. The caspase-1 CARD filament forms a lefthanded one-start helical assembly consisting of approximately four subunits per turn, a configuration similar to that of the Myddosome DD complex and the MAVS CARD filament 22, 24 , on the basis of the three previously defined types of asymmetric interactions 4, 25 ( Fig. 2b) . The type III interface exhibits interactions in the helical-strand direction. The type I and type II interfaces provide interaction between the helical turns (Fig. 2c) . The type I interface is the most extensive of the three types, with electrostatic complementarity (Fig. 2d) . Because of the potential inaccuracies in side chain conformations at this resolution, we describe the type Ia patch as collectively involving residues in helices α1 and α4 (such as K11, R10, R15, R55, and D52), which interact with residues in helix α2 (such as Q31, E28, D27, and N23) (Fig. 2e) . In contrast, the type II interaction requires an exposed hydrophobic residue, Y82 in the α5-α6 loop of one subunit, to be inserted into the α2-α3 loop of the adjacent subunit (Fig. 2f) . The type III interface appears to be the least extensive and may contribute less binding energy during filament formation (Fig. 2g) .
To validate the importance of these interfacial residues, we generated site-directed mutants and compared their properties with those of wild-type (WT) caspase-1 CARD (Fig. 2h,i) . We used GFP-tagged caspase-1 CARD for these experiments because the fusion protein primarily formed soluble short filaments, similarly to the GFP-AIM2 PYD protein 26 . We first analyzed whether the mutations reduced the aggregation tendency of GFP-tagged a a r t i c l e s npg a r t i c l e s caspase-1 CARD by using size-exclusion chromatography. We then determined whether the mutations decreased the ability of GFPtagged caspase-1 CARD to promote filament formation of WT monomeric caspase-1 CARD by using fluorescence polarization (FP).
For the second experiment, we added a C-terminal sortase motif to the His-MBPcaspase-1 CARD -SUMO construct used for cryo-EM. We labeled the fusion protein with the fluorophore TAMRA with recombinant sortase A 27 ( Fig. 1a) and initiated caspase-1 CARD polymerization by removal of the His-MBP tag by the TEV protease. WT GFP-caspase-1 CARD , which formed short filaments 5 , robustly nucleated caspase-1 CARD polymerization, as indicated by increased FP values (Supplementary Fig. 2 ). The apparent nucleation potency of WT GFP-caspase-1 CARD was ~283.0 ± 1.4 nM (Supplementary Fig. 2 ). Whereas GFP-tagged WT caspase-1 CARD eluted exclusively in the void volume of a Superdex 200 gel-filtration column, chargereversal mutations at the type Ia (R10E K11E) and Ib (D27R E28R) patches abolished formation of caspase-1 CARD filaments, thus reflecting the importance of electrostatic interactions at the type I interface (Fig. 2h) . The Y82E mutation at the type IIb patch also completely abolished filament formation. In contrast, the charge-reversal mutation at the type IIa patch, K64E, only impaired but did not abrogate filament formation, thus suggesting that the type II interface is probably contributed predominately by hydrophobic interactions. In the caspase-1 CARD polymerization assay, K64E was completely incapable of nucleating WT caspase-1 CARD filament formation (Fig. 2i) . Charge-reversal mutations at the type IIIa patch (K37E or R45E) did not affect either filament formation or nucleation. Only a triple mutation (T49R V50R M51R) at the type IIIb surface impaired aggregation and nucleation potency (Fig. 2h,i) , consistently with less extensive of type III interactions.
These results strongly correlated with our analysis of the caspase-1 CARD cryo-EM structure.
Caspase-1 CARD filament versus other DD complexes
We compared the structure of the caspase-1 CARD filament to the structures of other existing DD-fold complexes by pairwise structural alignment between isolated dimers of caspase-1 CARD and dimers of other DD-fold complexes. Within the CARD subfamily, MAVS CARD is the only other high-resolution filament structure recently determined by cryo-EM. Although both domains have very low sequence identity, the helical parameters of MAVS CARD and caspase-1 CARD are similar, perhaps owing to the relative location of the interfaces (Supplementary Fig. 3a-c) . We also compared the buried residues with respect to each type of interaction and found that the relative location of these residues indeed correlated very well between the two CARDs (Supplementary Fig. 3d ). For a quantitative comparison, we aligned one subunit of each interface type and measured how much rotation was required to overlap the other subunit (Supplementary Fig. 3e) 
INCA displays properties distinct from those of caspase-1 and ICEBERG
We expressed histidine-tagged human INCA and ICEBERG, and found that whereas INCA was soluble and monomeric, ICEBERG was largely insoluble (Fig. 3a,b) . To investigate the biochemical properties of ICEBERG, we fused it to the C terminus of His-MBP to increase its solubility. His-MBP-ICEBERG was soluble but eluted in the void volume of a Superdex 200 size-exclusion column. Removal of the His-MBP tag resulted in the formation of long and bundled filaments, as shown by negative-stain EM (Fig. 3c) . The NMR structure of ICEBERG solved at pH 3.8, under which the protein is monomeric 16 , shows a typical CARD structure with a six-helix bundle fold highly similar to that of ASC CARD (ref. 28) . INCA shares similar predicted secondary structures and 55% sequence identity with ICEBERG with no gaps in the alignment, thus suggesting that INCA may have a structure highly similar to that of ICEBERG (Fig. 3d) . However, ICEBERG and INCA have contrasting biophysical properties in solution. Because sequence comparisons revealed identities of 53% for ICEBERG and caspase-1 CARD , and 83% for INCA and caspase-1 CARD (Fig. 3d) , it is therefore the less homologous ICEBERG that has a filament-forming ability similar to that of caspase-1 CARD , whereas INCA is monomeric.
ICEBERG promotes and INCA inhibits formation of caspase-1 CARD filaments
We used the caspase-1 CARD polymerization assay to probe the effects of the COPs on caspase-1 polymerization. After removal of the His-MBP tag by addition of TEV protease, caspase-1 CARD -SUMO formed filaments at a negligibly slow rate, as shown by the minimal change in FP (Fig. 4a) . ICEBERG greatly enhanced formation of caspase-1 CARD filaments, thus suggesting that oligomeric ICEBERG provided seeds for polymerization of monomeric caspase-1 CARD .
In contrast, addition of INCA did not have substantial effects on caspase-1 CARD filament formation at its low basal rate. In ASC-dependent inflammasomes, the CARD of the adaptor ASC nucleates caspase-1 CARD polymerization 5 . To recapitulate this scenario in vitro, we expressed His-GFP fused to ASC CARD , the majority of which eluted in the void volume of a Superdex 200 size-exclusion column (Fig. 4b) . Negative-stain EM indicated that the protein formed short His-GFP-ASC CARD filaments (Fig. 4c) . Addition of these ASC CARD filaments at levels well below stoichiometry robustly potentiated caspase-1 CARD polymerization, with an apparent dissociation constant (K app ) of 108.0 ± 1.4 nM (Fig. 4d) . Using fixed His-GFP-ASC CARD and caspase-1 CARD concentrations, we added substoichiometric amounts of INCA and measured the rates of filament formation. Notably, very low concentrations of INCA were sufficient to substantially inhibit caspase-1 CARD filament formation (Fig. 4e) . The apparent inhibitory constant (K i ) was 9.4 ± 1.4 nM (Fig. 4e) .
To address the question of whether ICEBERG interacts with ASC CARD , we designed an ASC CARD polymerization assay similar to the caspase-1 CARD assay. We expressed and purified monomeric His-MBP-ASC CARD -SUMO with a C-terminal sortase motif and Fig. 4a ). Moreover, ICEBERG did not inhibit His-GFP-ASC CARDnucleated ASC CARD polymerization (Supplementary Fig. 4b ). Hence, we conclude that there is no apparent interaction between ICEBERG and ASC CARD .
INCA directly inhibits caspase-1 polymerization
The inhibitory effect of INCA with low-nanomolar potency in ASC CARD -induced caspase-1 CARD polymerization was remarkable.
To determine whether INCA directly interacts with ASC or caspase-1, we coexpressed the proteins in pairs. We cloned INCA into the pDW363 vector with an N-terminally fused biotin-acceptor peptide (BAP), which allows biotinylation in E. coli by the biotin ligase BirA expressed from the same vector 29 . We first coexpressed biotinylated INCA with His-GFP-ASC CARD . Ni-NTA affinity purification and gel-filtration chromatography yielded strong Coomassie blue-stained bands of His-GFP-ASC CARD but no bands of copurified INCA (Fig. 5a) . Streptavidin western blotting revealed a weak band of biotinylated INCA that copurified with His-GFP-ASC CARD (Fig. 5a) . To clarify whether this apparent weak interaction has any functional importance, we assessed the ability of INCA to inhibit this process in the ASC CARD polymerization assay. Suprastoichiometric amounts of INCA, at up to 10 µM, did not inhibit His-GFP-ASC CARD -nucleated ASC CARD filament formation (Fig. 5b) , thus suggesting that the ASC CARD -INCA interaction does not exert any functional effect.
To determine whether INCA interacts with caspase-1 CARD , we coexpressed the BAP-INCA fusion with His-GFP-caspase-1 CARD . Unlike His-GFP-ASC CARD , His-GFP-caspase-1 CARD copurified with sufficient amounts of INCA to be visible on Coomassie blue-stained SDS-PAGE at 7 and 8 ml (Fig. 5c) . Streptavidin western blotting further confirmed that the bands were biotinylated INCA, thus demonstrating a direct interaction between INCA and caspase-1 CARD . CARD domains of both ASC and caspase-1 were present in the assays that we used to demonstrate inhibition of caspase-1 polymerization by INCA (Fig. 4e) . The assay was thus not suitable to determine whether INCA acts on CARD domains of ASC or caspase-1. We therefore performed an alternative experiment using His-GFP-caspase-1 CARD as the nucleator. As described above, His-GFP-caspase-1 CARD and His-GFP-ASC CARD were similarly potent in nucleating monomeric caspase-1 CARD into extended filaments (Fig. 4d and Supplementary  Fig. 2) . Addition of INCA at very low concentrations dramatically inhibited His-GFP-caspase-1 CARD -induced caspase-1 CARD polymerization (Fig. 5d) . The K i was 4.3 ± 1.4 nM, a value similar to that obtained in His-GFP-ASC CARD -induced caspase-1 CARD polymerization (Fig. 4e) . We also subjected the His-GFP-caspase-1 CARDbiotinylated INCA complex (Fig. 5c) to streptavidin-gold and Ni-NTA-gold labeling and observed that INCA localized exclusively at the tip of caspase-1 CARD filaments (Fig. 5e,f) .
The concentrations of monomeric caspase-1 CARD and the preformed filamentous nucleators used in the polymerization assays a r t i c l e s only the filamentous form of caspase-1. This interaction directly occurred on the His-GFP-caspase-1 CARD filaments. When we used His-GFP-ASC CARD filaments, monomeric caspase-1 polymerized on these nucleators. Then His-GFP-ASC CARD -caspase-1 CARD complex filaments became able to directly interact with INCA. It is conceivable that in both cases, the nucleators were capped with INCA, thus leading to inhibition of polymerization.
On the basis of the gold-labeling experiment (Fig. 5e,f) , we quantitatively estimated this strength of inhibition by capping. The average length of the His-GFP-caspase-1 CARD filaments was ~150 nm, on the basis of the electron micrographs. We derived a similar length estimate for His-GFP-ASC CARD filaments (Fig. 4c) . Given the observed axial rise per subunit of 5.1 Å for the caspase-1 CARD filament, the total number of subunits per filament was ~30 (Fig. 1d) . This result suggests that the effective concentration of His-GFP-caspase-1 CARD nucleator would be ~30-fold lower, approximately 3 nM, a value in the same order of magnitude as the K i of INCA inhibition. Collectively, these data are consistent with the conclusion that INCA inhibits To test this hypothesis, we performed gel-filtration analysis to investigate whether His-MBP-caspase-1 CARD -SUMO formed complexes with INCA. We incubated caspase-1 CARD , at a concentration equivalent to that in the FP assays, with TEV for 90 min at room temperature to remove the N-terminal His-MBP in the presence or absence of a slightly suprastoichiometric amount of INCA. We expected caspase-1 CARD -SUMO to remain mostly monomeric in the absence of a nucleator (as in Fig. 4a) . Upon completion of the polymerization reaction, we injected the mixtures of MBP-cleaved caspase-1 and INCA onto a Superdex 200 column to determine whether a stable complex had formed. No apparent shift in the elution position was present when we ran the two proteins individually or as a mixture (Supplementary Fig. 5 ). This result suggests that INCA does not form a stable complex with caspase-1 CARD and consequently sequester the monomeric form but instead caps the oligomeric form.
ICEBERG interacts with caspase-1 CARD filaments
To test whether ICEBERG directly interacts with caspase-1 CARD , we used a similar strategy as used for INCA and coexpressed biotinylated ICEBERG and His-GFP-caspase-1 CARD . Ni-NTA pulldown showed copurified biotinylated ICEBERG, although in an amount substoichiometric to His-GFP-caspase-1 CARD , as confirmed by streptavidin western blotting (Fig. 6a) . In size-exclusion chromatography, the complex eluted in the void fraction (Fig. 6b) . We labeled the complex with Ni-NTA-gold and streptavidin-gold conjugates separately and subjected it to negative-stain EM analysis to probe the locations of the two proteins in the complex (Fig. 6c,d) . The labeling results showed that both gold conjugates randomly labeled the body of the filaments, indicating that ICEBERG copolymerized with caspase-1 CARD 
INCA inhibits NLRP3-inflammasome activation in THP-1 cells
Caspase-1 processing and IL-1β secretion are hallmarks of inflammasome activation. We assayed both to monitor the effect of inducible expression of ICEBERG or INCA in THP-1 cells under physiological conditions (Fig. 7) . We generated THP-1 cell lines expressing either INCA or ICEBERG and induced expression of the transgenes by the addition of doxycycline for 24 h before the experiments. Importantly, we withdrew doxycycline before inflammasome activation because we noticed that expression of any transgene during inflammasome activation impaired IL-1β secretion (data not shown). We then treated cells for 3 h with LPS and for 45 min with nigericin to induce NLRP3-inflammasome assembly. We first analyzed the processing of caspase-1 by immunoblotting, which showed that INCA expression efficiently inhibited the appearance of the processed forms, whereas ICEBERG expression had minimal effects (Fig. 7a) . Consistently with these results, the secretion of IL-1β in WT THP-1 cells and in uninduced cell lines was comparable, as quantified by ELISA (Fig. 7b) . Expression of INCA efficiently inhibited IL-1β secretion in LPS-and nigericin-treated cells, whereas expression of EGFP did not impair IL-1β secretion. Expression of ICEBERG did not have a substantial effect on IL-1β secretion (Fig. 7b) .
Therefore, in agreement with our in vitro data, the cellular experiments support a model in which INCA efficiently perturbs caspase-1 cleavage and activity, presumably because of the inhibition of caspase-1 polymerization. In contrast, ICEBERG did not appear to inhibit NLRP3-dependent inflammasome activation, caspase-1 oligomerization, and caspase-1 activity. However, the situation in cells is substantially more complex, and it is conceivable that ICEBERG levels are insufficient or that ICEBERG binding to caspase-1 CARD is subject to regulation by cellular proteins. The question of whether ICEBERG is a genuine inflammasome inhibitor remains to be answered. Even though it physically interacts with caspase-1, the exact molecular mechanism of regulation is unclear.
Structural mechanism of caspase-1 inhibition by INCA
The tendency of DD-fold family proteins to oligomerize into helical oligomers has been extensively demonstrated. Examples of DD helical structures include the PIDDosome (DD) 25 , Myddosome (DD) 24 , ASC filament (PYD) 5 , and MAVS filament (CARD) 22 . To our knowledge, ours is the first reported CARD-filament structure in the inflammasome pathway. For INCA to interact with caspase-1, we predict that it must use CARD-CARD interaction surfaces similar to those observed in the caspase-1 CARD filament structure. Hence, we superimposed a predicted INCA monomer model based on the NMR structure of ICEBERG onto the caspase-1 CARD filament structure, to visualize the subtle differences between INCA and caspase-1 CARD underlying INCA's inhibitory mechanism ( Fig. 8 and Supplementary Fig. 6 ).
For the type I interaction, INCA has a highly similar type Ia interface, marked by the conserved R15 and R55 between caspase-1 and INCA. Strikingly, Asp27 on the caspase-1 type Ib surface has changed to Gly27 in INCA (Fig. 8a) . This change probably renders the type Ib interface in INCA defective for interaction. According to our mutagenesis studies on caspase-1, type Ib mutation (D27R E28R) completely disrupted filament formation and resulted in the monomeric form of caspase-1 (Fig. 2h) . The type II interface is primarily hydrophobic in caspase-1, which relies on Tyr82 for the interaction (Fig. 2f,h) . The corresponding position in INCA has changed to His82 (Fig. 8b) , which probably renders its type IIb interface defective for interaction. The type III interface represents the least extensive interface and is mostly conserved between INCA and caspase-1 CARD (Fig. 8c) .
As a result, we propose a model of how INCA inhibits caspase-1 CARD via a capping mechanism, based on the defective type Ib and IIb interfaces, and the intact type Ia, IIa, IIIa, and IIIb interfaces (Supplementary Fig. 6 ). During inflammasome activation by filament formation, and in the absence of the inhibitory protein INCA, oligomerized ASC CARD domains seed caspase-1 CARD filaments (Supplementary Fig. 6a ). In contrast, in the presence of INCA, a small caspase-1 CARD oligomer can stochastically recruit one or a few subunits of INCA through its intact type Ia, IIa, IIIa, and IIIb patches, thereby capping the growing caspase-1 filament. Owing to the defective type Ib and IIb patches in INCA, the capped filament then loses the ability to further recruit inactive monomeric caspase-1 (Supplementary Fig. 6b ). This capping mechanism explains the high inhibitory potency of INCA in blocking the formation of caspase-1 CARD filaments in our biochemical assay. 
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To test this model, we generated a charge-reversal mutant, R55E, at the type Ia interface of INCA, and tested its ability to inhibit GFPcaspase-1-nucleated caspase-1 CARD filament formation. Type Ia contains basic residues that are essential for forming the electrostatic interactions between neighboring CARDs. Therefore, we expect this mutation in INCA to lower its affinity for the caspase-1 CARD oligomer and thereby abolish its ability to cap the growing caspase-1 CARD filament. As expected, the R55E mutation substantially reduced the inhibition potency (Supplementary Fig. 7) . When we increased the concentrations of R55E in the polymerization assay to drive the inhibition, we derived a K i of ~1.7 µM for R55E, which is ~400-fold higher than that of WT INCA, thus supporting our proposed capping mechanism.
DISCUSSION
An emerging theme in the field of innate immunity involves the discovery of higher-order signalosomes in ligand binding and signal transduction 30 . The inflammasome assemblies, in particular, use a nucleated polymerization mechanism 5 . Through the formation of filaments and elaborate aggregates in the cell, component proteins come together for efficient activation and signal amplification 5, 6 . This mechanism has also been observed in the RIG-I pathway 22, 31 and the CARMA1-Bcl10-MALT1 pathway 32 and can be further generalized to related DD-foldcontaining proteins in other pathways. Extending the initial discovery of INCA as an inhibitor of LPS-induced and caspase-1-dependent IL-1β secretion 1 , we investigated its mechanism of inhibition in the context of higher-order inflammasome assemblies. We found that INCA is a highly efficient inhibitor of caspase-1 CARD oligomerization, with an apparent K i in the nanomolar range. We conclude from our biochemical and structural analyses that INCA caps small oligomers of caspase-1 CARD through CARD-CARD interactions, thereby preventing the further recruitment of inactive caspase-1 monomers and the elongation of the CARD filaments (Supplementary Fig. 8 ).
For ICEBERG and COP1, unlike INCA, future studies are required to elucidate their functional mechanisms. ICEBERG oligomerizes and commingles with caspase-1. COP1 has two isoforms: a short isoform with CARD only and a longer isoform with an additional ~100 residues at the C-terminal end. COP1 CARD differs from caspase-1 CARD in only three residues, two of which, H15 and Q37, reside at the predicted filamentous interface (Fig. 3d) . However, H15 and Q37 are identical in ICEBERG, and therefore these differences should not affect the interaction of COP1 with caspase-1. Hence, like ICEBERG, COP1 may also commingle with caspase-1 filaments. It remains to be determined whether ICEBERG and COP1 are bona fide inflammasome inhibitors, because our cellular assay did not show any inhibition of NLRP3-inflammasome activation by ICEBERG.
Numerous studies have suggested that inflammasomes may represent important therapeutic targets against human diseases. For example, genetic evidence in the inflammasome sensor proteins NLRP3 (172 known disease variants), Pyrin (also known as MEFV; 297 known disease variants), PSTPIP1 (22 known disease variants), and NLRP12 (32 known disease variants) has linked inflammasomes to hereditary periodic fevers, inflammation, and autoimmunity. More importantly, overactivation of inflammasomes is causal for or associated with highly prevalent inflammatory diseases within and outside the immune system 1, 3, 33 , including gout, rheumatoid arthritis, dermatitis, lung fibrosis 34 , irritable and inflammatory bowel diseases 35 , neuropathic pain, sepsis, obesity, atherosclerosis 36 , diabetes 37, 38 , and gastric carcinoma. Many of these diseases have limited treatment options, particularly those that specifically address the root of the inflammatory response. The capping mechanism by INCA discovered here permits interference of inflammasome assembly at a highly substoichiometric ratio and provides a new potential therapeutic strategy for inhibition of inflammasomes as well as the many other innate immune signaling complexes that use DD-fold domains as the main scaffolding architectures.
Our work also reveals an unexpected mechanistic connection to capping proteins that dynamically regulate cellular cytoskeletal networks. For instance, the dimeric protein CapZ seals the barbed end of actin filaments, thereby preventing their elongation [39] [40] [41] . Human CapZ has a K app of ~3 nM in actin elongation and depolymerization assays 41 . This value is comparable to that of INCA in our caspase-1 polymerization assay. Fungal metabolites known as cytochalasins, which bind actin filaments and block their polymerization, are another example 42 . The effective concentrations of these molecules can range between hundreds of picomolar to several micromolar in cells 43 . The apparent equilibrium dissociation constant of cytochalasin D for ADP-actin is ~1-2 nM (ref. 44) . Collectively, our findings suggest that INCA may well be the equivalent of the CapZ or cytochalasin inhibitors in caspase-1 filament elongation, and they illustrate a potential new therapeutic mechanism for inflammasomeassociated diseases.
METHODS
Methods and any associated references are available in the online version of the paper. 
